18:47 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest promoting expression of the miR-371-373 cluster encoding miR-371, miR-372 and miR-373 or inhibiting the TGFβ-RII/ID1 axis could help treat colorectal cancer. In colorectal cancer...
23:16 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Mouse studies suggest increasing expression of ID2 in dendritic cells (DCs) could improve the antitumor efficacy of DC vaccines for cancer. In a mouse model of melanoma, intratumoral injection of DCs overexpressing vector-encoded...
07:00 , Nov 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest promoting ID2 expression or inhibiting TCF4 could help treat PGC-1α-deficient metastatic melanoma. In primary tumor samples from 68 melanoma patients, invasive tumor pathology was associated with low levels...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α, to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While the findings...
07:00 , May 14, 2015 |  BC Innovations  |  Translation in Brief

Check Your ID

A new pathway of immune suppression has been uncovered in a joint study by Regeneron Pharmaceuticals Inc. and researchers at Weill Cornell Medical College that positions inhibitor of DNA binding 1 (ID1) as a key...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Inhibitor of DNA binding 1 (ID1)

Cancer INDICATION: Cancer Studies in patients and mice suggest inhibiting ID1 could help treat cancer. In peripheral blood monocytes from patients with metastatic breast cancer or metastatic melanoma, ID1 levels were higher than in monocytes from healthy...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Activin receptor-like kinase 2 (ALK2; ACVR1); SMAD family member 1 (MADH1; SMAD1); inhibitor of DNA binding...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

AngioGenex preclinical data

In a mouse model of breast cancer, twice-daily AGX-51 significantly blocked tumor growth at a dose <7 mg/kg when given in combination with a taxane and completely blocked tumor-associated angiogenesis when given alone at a...
08:00 , Dec 19, 2013 |  BC Innovations  |  Targets & Mechanisms

Balancing act in liver fibrosis

CXCR7, one of the few chemokine receptors against which there are virtually no drug development efforts, may be a novel target for liver fibrosis, according to new findings from a U.S. team.1 The results also...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inhibitor of DNA binding 1 (ID1) Patient sample, mouse and cell culture studies suggest inhibiting...